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progression rates and OS in patients with primary tumor 
 excision and SLNB at the same time compared with patients 
with excisional biopsy of primary tumor and SLNB at differ-
ent times.  Conclusion: These data suggest that excisional 
biopsy of the primary tumor does not prevent the correct 
SLN mapping in melanoma patients. 
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 Introduction 
 The incidence of melanoma has increased significant-
ly in the last few decades. Surgery is the gold standard in 
the treatment of primary melanoma, while the histologi-
cal tumor thickness according to Breslow is decisive for 
safety margins and the indication for sentinel lymph 
node biopsy (SLNB). At present, SLNB is recommended 
at a tumor thickness greater than 1 mm  [1, 2] . The senti-
nel lymph node (SLN) is the first regional lymph node on 
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 Abstract 
 Background: Sentinel lymph node biopsy (SLNB) has be-
come the standard care for melanoma and is an important 
diagnostic procedure. It has been doubted whether lympho-
scintigraphy detects the correct sentinel lymph node (SLN) 
when excision of the tumor and SLNB are not performed at 
the same time. This would imply that this sequential ap-
proach may have an increased risk of undetected microme-
tastases resulting in a worse outcome. Objective: The pur-
pose of the present study was to compare the outcome of 
melanoma patients having received excision of the tumor 
and SLNB either at the same time or consecutively.  Methods: 
A total of 854 patients with cutaneous melanoma were en-
rolled in this retrospective study between September 1996 
and November 2007. Disease-free (DFS) and overall survivals 
(OS) were estimated using the Kaplan-Meier product limit 
method and were analyzed by the log rank test.  Results: No 
statistically significant difference was found regarding DFS, 
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the direct lymphatic pathway from the primary melano-
ma. If tumor cells have metastasized, they are most likely 
located in the SLN. SLNB was initially described by Mor-
ton et al. [3] and is recognized as an important diagnostic 
procedure with a great prognostic value, while a thera-
peutic benefit has not been shown yet.
 In most skin cancer centers in Europe, SLNB is per-
formed according to European melanoma guidelines 
with two common approaches  [1, 4, 5] : (i) excisional bi-
opsy of the primary tumor with histological confirma-
tion of tumor type and thickness followed by a wide exci-
sion (1 cm and more) and SLNB, or (ii) wide excision of 
the primary tumor and SLNB at the same time, provided 
that the clinical diagnosis is obvious, possibly supported 
by dermoscopy and by high-frequency ultrasound for the 
preoperative evaluation of tumor thickness  [6–8] .
 It is still controversially discussed how far the surgical 
procedure of the excisional biopsy of the primary tumor 
alters the lymphatics leading to different draining SLNs. 
It has been questioned whether lymphatic mapping shows 
consistent results with or without prior excisional biopsy 
of the primary melanoma. It was hypothesized that a 
nonidentical lymphatic mapping would lead to an in-
creased probability of false-negative SLNB and thus high-
er rates of progressive disease, especially of regional 
lymph node metastases.
 Patients and Methods 
 At our dermatology unit, 1,049 consecutive patients had been 
identified for SLNB between September 1996 and November 
2007. Most of them presented with cutaneous melanomas with a 
Breslow thickness  1 1 mm or with other risk factors such as ulcer-
ation or regression of primary melanoma as well as Clark level IV 
and V. No SLN could be detected in 29 out of 1,049 patients (2.76%) 
for technical reasons. Thus, the detection rate was 97.24%. In 166 
patients, missing information concerning tumor type, tumor 
thickness, Clark level or follow-up data led to the exclusion from 
the study. Therefore, a total of 854 patients could be enrolled in 
this study.
 In patients with clinical suspicion of melanoma, the diagnosis 
was corroborated using dermoscopy. A measurement of tumor 
thickness was performed preoperatively using 20-MHz high-fre-
quency ultrasound (DUB 30, Taberna pro medicum, Lüneburg, 
Germany)  [6–8] .
 Postoperatively, the median tumor thickness was 2.15 mm as 
determined histologically. If excisional biopsy of the primary 
melanoma had been performed elsewhere, the original slides were 
re-examined by an experienced dermatopathologist (M.F.) at our 
department. The primary tumor was excised within 4 weeks pri-
or to SLNB (n = 549) or at the same time as SLNB (n = 305). A 
safety margin of 1 cm was chosen for primary tumors up to 2 mm 
in thickness, while thicker tumors were excised with a safety mar-
gin of 2 cm according to the German melanoma guidelines. In 
most patients with both surgical procedures at different time 
points, excisional biopsy of the primary tumor was performed at 
first followed by a wide excision (1 cm or more) together with 
SLNB.
 In only 4 patients had primary tumor excision already been 
performed with a safety margin of 1 cm.
 SLNB Procedure 
 Two to 16 h prior to SLNB, dynamic lymphoscintigraphy was 
performed using technetium-99m-labeled human serum albu-
min colloid (Solco-Nanokoll, Sorin-Biomedica, Munich, Germa-
ny) in collaboration with the Department of Nuclear Medicine, 
University of Munich. The skin site corresponding to the hottest 
emission point was marked. On the day of surgery, a hand-held 
gamma camera (C-Trak System, Care Wise, Morgan Hill, Calif., 
USA) was used to measure background and SLN radioactivity 
pre- and intraoperatively. In addition, intradermal injection of 
0.5–1.0 ml of patent blue V (Guerbet, Sulzbach, Germany) was 
performed 10–15 min preoperatively about 0.5 cm around the pri-
mary tumor or excision scar. The SLN was identified as a hot and 
blue-stained lymph node. SLNB was performed using standard 
procedures. All lymph nodes exhibiting radioactive impulse rates 
of at least 10% of the lymph node with the maximal radioactive 
impulse rate were surgically removed  [9] .
 Histopathological Evaluation 
 For histopathological examination, the SLN was bisected 
along the long axis after formalin fixation. From each paraffin 
block, 8–12 sections were prepared for staining with hematoxylin 
and eosin and Giemsa as well as for immunohistochemical analy-
sis (S100, HMB45, NKiC3, Melan A). The tumor load was docu-
mented for each SLN concerning location within the lymph node 
and size (micrometastasis and macrometastasis). Lymph nodes 
with histologically proven deposits of more than 3 tumor cells 
were considered metastatic. Primary tumors and the specimens 
from complete lymphadenectomies were examined using routine 
histology  [9] .
 Surgical and Adjuvant Therapies 
 Patients  with  metastases  in  the  SLN (213/854 patients; posi-
tive SLN) were recommended to undergo a radical lymph node 
dissection of the regional basin  [9] . Of these, 176 patients (83%) 
underwent this procedure. The lymph nodes of the neck were 
 removed by a modified neck dissection, the axillary nodes by a 
level II dissection and the inguinal nodes by an ilioinguinal dis-
section (cranially up to the iliac bifurcation and caudally to the 
apex of the femoral triangle). All patients with primary melanoma 
 6 1.5 mm thickness as well as patients with positive SLN were 
considered for low-dose   -interferon therapy (3  ! 3 million IU 
s.c. per week). The adjuvant treatment courses were not recorded 
in detail for this study, but they were performed according to 
study protocols of the German Dermatologic Cooperative Oncol-
ogy Group  [10] . The duration of adjuvant treatment varied be-
tween 18 and 60 months.
 Statistical Analysis 
 The association of patient and tumor characteristics with time 
point of lymphatic mapping (1 vs. 2) was assessed by the   2 test. 
Disease-free (DFS) and overall survival (OS) curves were estimat-
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ed using the Kaplan-Meier product limit method and were ana-
lyzed for significant differences by the log rank test. The signifi-
cance level was determined at p  ! 0.05. To assess the risk of dif-
ferent surgical procedures on DFS and OS with respect to the 
impact of different tumor- and patient-related factors, we calcu-
lated 3 models using Cox regression analysis with different ad-
justments.  The analyses were performed with the statistical soft-
ware package SPSS, version 16.0 (Chicago, Ill., USA).
 Follow-Up 
 The follow-up of all patients was conducted by clinical exam-
ination and ultrasound of regional lymph nodes at our dermatol-
ogy unit in intervals according to the German follow-up guide-
lines. Tumor progression as well as survival was documented, ad-
ditionally.
 Results 
 The distributions of patient and tumor characteristics 
for all patients stratified by time point of lymphatic map-
ping are shown in  table 1 . The median age of all patients 
was 55 years (range 9–83 years); 485 were male (56.8%) 
and 369 female (43.2%). Almost half of the patients 
(49.7%) were between 51 and 70 years of age. The median 
tumor thickness was 1.6 mm (range 0.2–19 mm). The 
time point of lymphatic mapping was significantly asso-
ciated with all patient and tumor characteristics except 
for the Clark level.
 To determine if the sequence of surgical procedures 
(excisional biopsy of the primary melanoma and subse-
quent SLNB at different time points vs. wide excision of 
the primary melanoma and SLNB at the same time) had 
a significant effect on the course of the disease, survival 
analysis (Kaplan-Meier estimator with log rank tests for 
bivariate comparisons) was performed.
 Description of Outcome Analysis 
 A total of 1,491 SLNs were excised in 854 patients 
(mean 1.75 per patient). A total of 549 patients underwent 
excisional biopsy of the primary melanoma and SLNB at 
different time points (group 1), while 305 patients re-
ceived both surgical interventions at the same time 
(group 2). In group 1, 88 (16%) of 594 patients developed 
progression of disease compared to 59 (19.3%) of 305 pa-
tients in group 2 ( table 2 ). There was no significant dif-
ference with respect to the mode of progression, i.e. me-
tastasis in the regional lymphatic basin, either: in group 
1, progression in regional lymph nodes was found in 20 
patients (3.6%) compared to 15 patients (4.91%) in group 
2 (p = 0.34;  table 2 ).
Table 1.  Clinical and pathological characteristics of the study 
population (n = 854)
Complete
study
population
Tumor excision 
and SLNB at the 
same time
Tumor excision 
and SLNB 
 consecutively
p
value
Sex
Male 485 (56.8) 192 (63) 293 (53.4) 0.007
Female 369 (43.2) 113 (37) 256 (46.6)
Age, years
Mean 55 55.33 51.66
Minimum 9 18 9
Maximum 83 83 80
Age groups
^40 177 (20.7) 39 (12.8) 138 (25.1)
41–50 174 (20.4) 67 (22) 107 (19.5)
51–60 214 (25.1) 81 (26.6) 133 (24.2)
61–70 210 (24.6) 83 (27.2) 127 (23.1)
170 79 (9.3) 35 (11.5) 44 (8)
Localization of primary tumor
Head 48 (5.6) 19 (6.2) 29 (5.3) <0.001
Body 376 (44.0) 145 (47.5) 223 (42.1)
Upper extremity 112 (13.1) 27 (8.9) 85 (15.5)
Lower extremity 245 (28.7) 72 (23.6) 173 (31.5)
Acral 73 (8.5) 42 (13.8) 31 (5.6)
Tumor thickness, mm
Mean 1.6 2,103 2,178 <0.001
Minimum 0.2 0.2 0.45
Maximum 19 14 19
Thickness classes
^0.75 mm 53 (6.2) 40 (13.1) 13 (2.4)
0.76–1.00 94 (11.0) 38 (12.5) 56 (10.2)
1.01–1.50 262 (30.7) 63 (20.7) 199 (36.2)
1.51–2.00 159 (18.6) 63 (20.7) 96 (17.5)
2.01–4.00 211 (24.7) 70 (23) 141 (25.7)
14.00 75 (8.8) 31 (10.2) 44 (8)
Clark level
II 19 (2.2) 11 (3.6) 8 (1.5) 0.230
III 309 (36.2) 107 (35.1) 202 (36.8)
IV 493 (57.7) 176 (57.7) 317 (57.7)
V 33 (3.9) 11 (3.6) 22 (4)
Histological subtype
NM 318 (37.2) 95 (31.1) 223 (40.6) <0.001
SSM 283 (33.1) 113 (37) 170 (31)
SNSSM 133 (15.6) 55 (18) 78 (14.2)
Spitzoid melanoma 34 (4.0) 1 (0.3) 33 (6)
ALM 46 (5.4) 34 (11.1) 12 (2.2)
Other 40 (4.7) 7 (2.3) 33 (6)
Further characteristics
Not specified 302 (35.4) 103 (33.8) 199 (36.2) <0.001
Nodular 161 (18.9) 45 (14.8) 116 (21.1)
Secondary nodular 110 (12.9) 43 (14.1) 67 (12.2)
Nevus associated 96 (11.2) 26 (8.5) 70 (12.8)
Ulceration 81 (9.5) 25 (8.2) 56 (10.2)
Regression 42 (4.9) 30 (9.8) 12 (2.2)
Other 62 (7.3) 33 (10.8) 29 (5.3)
NM = Nodular melanoma; SSM = superficial spreading melano-
ma; SNSSM = secondary nodular superficial spreading melanoma; 
ALM = acral lentiginous melanoma. Figures in parentheses are per-
centages.
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 Results of Survival Analysis 
 Patients who had undergone both surgical interven-
tions at different time points (group 1) showed a DFS of 
110.2 months, while patients with excision of the primary 
tumor and SLNB at the same time (group 2) had a DFS of 
104.54 months (p = 0.472). The OS in group 1 was 113.39 
months compared to 113.2 months in group 2 (p = 0.844). 
As these differences between both groups were not statis-
tically significant, the sequence of surgical procedures did 
not seem to affect the risk of tumor progression ( table 3 ).
 A subdivision of the two groups with respect to the 
presence of SLN metastasis showed no significant differ-
ence in DFS: patients with positive SLNs in group 1 had 
a median DFS of 82.11 months compared to 77.65 months 
in group 2 ( fig. 1 ; p = 0.805). Patients with negative SLNs 
in group 1 had a median DFS of 118.7 months compared 
to 113.96 months in group 2 ( fig. 2 ; p = 0.805).
 The time point of lymphatic mapping was not signifi-
cantly associated with DFS or OS as shown by calculating 
3 models using Cox regression analysis with different ad-
Table 2.  Association between sequence of surgical procedure and kind of progression
No
progression
P rogression Total
lymph node relaps e other sum
Tumor excision and SLNB at the same time 246 (80.7%) 15 (4.91%) 44 (14.42%) 59 (19.3%) 305 (100%)
Tumor excision and SLNB consecutively 461 (84%) 20 (3.6%) 68 (12.4%) 88 (16%) 549 (100%)
Total 707 (82.8%) 35 (4.3%) 112 (13.3%) 147 (17.2%) 854 (100%)
Table 3.  Survival analysis using the Kaplan-Meier estimator
Tumor excision and SLNB DFS (log rank test:
p = 0.472), months
OS (log rank test:
p = 0.844), months
At the same time 110.02 113.39
Consecutively 104.54 113.2
Total 108.56 113.41
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 Fig. 1. DFS of patients with positive SLNs estimated by the Kap-
lan-Meier method. 
 Fig. 2. OS of patients with negative SLNs estimated by the Kaplan-
Meier method. 
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justments, notwithstanding the fact that all patient and 
tumor characteristics except for the Clark level were dif-
ferent in both groups. Hazard ratios in the model adjust-
ed for basic risk factors such as age, tumor thickness and 
histological subtype were 1.027 for DFS and 1.129 for OS 
(p values 0.877 and 0.532) and similar to the hazard ratios 
without adjustment ( table 4 ).
 The reliability of the lymph node mapping could also 
be demonstrated by 2 individual cases: in 2 patients, lym-
phoscintigraphy had been performed twice, i.e. before 
and after excisional biopsy of the primary melanoma, be-
cause the originally planned excision of the SLN had to 
be canceled due to the unintentional oral intake of met-
formin. Therefore, a few days later a second lymphoscin-
tigraphy was performed followed by SLNB and a wide 
excision with the recommended safety margins. In both 
cases, it seemed that the identical SLNs were mapped in 
the same regional lymphatic basins.  Figures 3 and  4 show 
the lymph node mapping before and after excision of the 
primary melanoma of the respective patients.
 Discussion 
 SLNB has become the gold standard in the surgical 
management of cutaneous melanoma with a Breslow 
thickness  1 1 mm  [2, 11–13] . In selected cases (young pa-
tient age, ulceration of the primary melanoma, Clark lev-
el IV or V, signs of regression), SLNB is also recommend-
ed in patients with melanomas thinner than 1 mm. The 
detection of micrometastasis in the SLN is the most im-
portant negative prognostic factor  [14, 15] . In case of SLN 
metastasis, regional lymph node dissection is commonly 
Table 4. M ultivariate analysis – survival and complete lymph node dissection by Cox regression
DFS O S
HR 95% CI p HR 95% CI p
Model I 0.886 0.637–1.233 0.473 0.963 0.662–1.401 0.844
Model II 0.952 0.683–1.327 0.771 1.092 0.749–1.591 0.648
Model III 1.027 0.733–1.438 0.877 1.129 0.772–1.650 0.532
HR = Hazard ratio; CI = confidence interval. Surgical modality was excision of the tumor and SLNB either 
at the same time or consecutively. Model I included the variable surgical modality. Model II included variables 
surgical modality, age and sex. Model III included variables surgical modality, age, sex, histological tumor type 
characteristics (nodular + secondary nodular + nevus, ulceration, regression, not specified + other), tumor 
thickness, histological tumor type (nodular melanoma, superficial spreading melanoma + secondary nodular 
superficial spreading melanoma, acral lentiginous melanoma, other + spitzoid) and localization of primary.
1st SLN
1st SLN
2nd SLN
2nd SLN
LN
RVL Left lat. Trunk: 30.0%Trunk: 30.0%
47 MBq 99mTc Nanocoll
Axilla
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SLN 2
Trunk: 90.0%RVL
SLN 2
Left lat.
b
 Fig. 3. Patient 1, lymphoscintigraphy before ( a ) and after excision 
( b ) of the primary tumor. RVL = Right/ventral/left. 
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recommended. While SLNB is accepted as an important 
diagnostic procedure, the opinions about a possible ther-
apeutic effect are very controversial, and data from large 
prospective clinical trials are still missing  [10, 16, 17] .
 Since SLNB is a standardized and well-established 
procedure in most skin cancer centers, its reproducibility 
is of the utmost importance  [18] . Previous studies have 
indicated that lymphoscintigraphy for lymphatic map-
ping in melanoma is reproducible  [19, 20] .
 Whether the time point of primary tumor excision 
and SLNB, i.e. at the same time or at a different time, af-
fects the accuracy of the lymph node mapping and con-
sequently the further course of disease is still under dis-
cussion. Frequently, primary tumor excision and SLNB 
are not carried out at the same time point. However, there 
are concerns that the patterns of afferent lymphatic flow 
from a primary tumor site may be altered as a result of 
disruption of the lymphatic vessels. This disruption may 
negatively impact on the identification of the SLN or the 
correct pathological status of the draining lymph node 
basins in these patients, since the actually identified 
drainage pathways may no longer represent the original 
ones of the primary tumor  [20, 21] . Consequently, SLNB 
could miss the true SLNs and identify false-negative 
SLNs. In these patients, the possible benefit of a complete 
lymph node dissection and of an adjuvant therapy at an 
early stage would not even be considered  [22] .
 These problems do not exist when the primary tumor 
excision and SLNB are performed at the same time. How-
ever, in many cases excisional biopsy of the primary tu-
mor is performed initially because the clinical diagnosis 
needs to be confirmed first and the tumor thickness of 
melanoma is uncertain  [23, 24] . Very commonly the pri-
mary excision takes place in a nonspecialized outpatient 
setting before the patients are then referred to the hospi-
tal for SLNB. Our present data show that 64.2% of the 
patients underwent excisional biopsy of the primary mel-
anoma and SLNB at different time points. Hence, a com-
plete understanding of the accuracy and validity of SLNB 
after excisional biopsy of the primary tumor is manda-
tory. The results of a univariate analysis show no signifi-
cant correlation between the sequence of surgical proce-
dures and general disease progression (p = 0.219), or with 
progression in regional lymph nodes either (p = 0.304). In 
fact, the number of relapses in regional lymph nodes was 
even lower in patients who had received excisional biopsy 
of the primary tumor and SLNB at different time points 
(3.6%) compared to patients who had both surgical pro-
cedures at the same time (4.91%). These data indicate that 
excisional biopsy of the primary tumor does not signifi-
cantly alter lymphatic vessels leading to different lym-
phatic drainage.
 Moreover, the sequence of surgical procedures does 
not seem to influence DFS and OS: there was no statisti-
cally significant difference in both groups regarding DFS 
(p = 0.472) and OS (p = 0.844). After differentiation of 
both groups into SLN-positive and SLN-negative pa-
tients, no differences concerning DFS and OS could be 
observed either.
 All patient and tumor characteristics except for the 
Clark level were different in both groups (primary tumor 
excision and SLNB performed at the same time or con-
secutively). A possible selection bias could be excluded by 
calculating 3 models using Cox regression analysis with 
different adjustments. 
SLN 1
Injection Left knee
Hip
a
RVL
SLN
Thigh
b
 Fig. 4. Patient 2, lymphoscintigraphy before ( a ) and after excision 
( b ) of the primary tumor. RVL = Right/ventral/left. 
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 The results of our study suggest that SLN mapping re-
mains accurate, even though excisional biopsy of the pri-
mary tumor and SLNB are performed at different time 
points, because this approach did not show higher rates 
of false-negative SLNs or worse survival rates. These re-
sults are supported by a previously published prospective 
study in which Trifiro et al. [25] could demonstrate that 
in 23 of 31 cases lymphoscintigraphy before and after ex-
cisional biopsy was concordant in terms of nodal basins 
visualized. False-negative results were obtained in 8 pa-
tients: in 2 patients, the second lymphoscintigraphy did 
not identify any lymph node basin, while an additional 
basin appeared in 6 patients. Other studies indicated that 
even after wide local excision (1 cm or more) including 
primary closure as well as split-thickness skin graft lym-
phatic mapping and SLNB were accurate  [22, 26–28] .
 Regional relapses (false-negative SLN) were only seen 
in patients who underwent rotation flap grafting prior to 
SLNB, so this procedure is considered to be a contraindi-
cation. In some cases, patients may show an increased 
number of SLNs and drainage to additional lymph node 
regions  [29] .
 In summary, regional lymph node mapping and SLNB 
subsequent to excisional biopsy of the primary tumor are 
accurate and have no other impact on OS and DFS com-
pared to both surgical procedures performed at the same 
time. 
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